MWNA
ELTX icon

Marshall Wace North America’s Elicio Therapeutics ELTX Stock Holding History

Marshall Wace North America’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,638
Closed -$1.2M – 1534
2021
Q1 		$1.2M Buy
+6,638
New +$1.28M 0.01% 983

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Marshall Wace North America's ELTX Position: Q2 2021 in Review

Marshall Wace North America sold out of Elicio Therapeutics (ELTX) in Q2 2021, closing a stake of 6,638 shares — an estimated $1.2M sold.

Marshall Wace North America first reported a position in ELTX in Q1 2021 and held it in 1 quarter. The position peaked at $1.2M in Q1 2021. 41 funds tracked by Wall St. Rank hold ELTX as of Q2 2021.

  • Marshall Wace North America reported no remaining Elicio Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 6,638 Elicio Therapeutics shares in Q2 2021, an estimated $1.2M.
  • Marshall Wace North America first reported a position in Elicio Therapeutics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Elicio Therapeutics position peaked at $1.2M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.